Statin prescriptions and breast cancer recurrence risk: A Danish nationwide prospective cohort study

Journal of the National Cancer Institute

Volumn 103, Issue 19, 2011, Pages 1461-1468

  Ahern, Thomas P ^a   Pedersen, Lars ^b   Tarp, Maja ^b   Cronin Fenton, Deirdre P ^b   Garne, Jens Peter ^c   Silliman, Rebecca A ^e   Sørensen, Henrik Toft ^b,d   Lash, Timothy L ^b,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d Danish Breast Cancer Cooperative Group   (Denmark)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ATORVASTATIN; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN RECEPTOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGE; AGED; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVOR; CONTROLLED STUDY; DATA BASE; DRUG SOLUBILITY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HYDROPHILICITY; LIPOPHILICITY; MAJOR CLINICAL STUDY; MENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BREAST NEOPLASMS; DENMARK; DRUG PRESCRIPTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LINEAR MODELS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; REGISTRIES; RISK FACTORS; SIMVASTATIN;

EID: 80054078528     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr291     Document Type: Review

References (53)

1. Brown MS, Goldstein JL. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res. 1980;21(5):505-517. (Pubitemid 11194847)
2. HMG-CoA Reductase Inhibitors. In: McEvoy GK, ed. American Society of Health Pharmacists Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2009.
3. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118. (Pubitemid 40261799)
4. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14(1):37-44.
5. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19(1):26-37. (Pubitemid 28094090)
6. Katz MS. Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol. 2005;2(2):82-89. (Pubitemid 40790141)
7. Sorensen HT, Riis AH, Lash TL, et al. Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes. 2010;3(4):413-417.
8. Mann D, Reynolds K, Smith D, et al. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother. 2008;42(9):1208- 1215.
9. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2008. Bethesda, MD; National Cancer Institute. http://seer.cancer. gov/csr/1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
10. Boudreau DM, Yu O, Buist DS, et al. Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control. 2008;19(7):767-774.
11. Eliassen AH, Colditz GA, Rosner B, et al. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med. 2005;165(19):2264-2271. (Pubitemid 41549923)
12. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer. 2005;114(4):643-647. (Pubitemid 40349625)
13. Setoguchi S, Glynn RJ, Avorn J, et al. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation. 2007;115(1):27-33. (Pubitemid 46058608)
14. Woditschka S, Habel LA, Udaltsova N, et al. Lipophilic statin use and risk of breast cancer subtypes. Cancer Epidemiol Biomarkers Prev. 2010;19(10):2479-2487.
15. Moysich KB, Beehler GP, Zirpoli G, et al. Use of common medications and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1564-1595.
16. Cauley JA, McTiernan A, Rodabough RJ, et al. Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst. 2006;98(10):700-707. (Pubitemid 43821787)
17. Boudreau DM, Gardner JS, Malone KE, et al. The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer. 2004;100(11):2308- 2316. (Pubitemid 38657877)
18. Bonovas S, Filioussi K, Tsavaris N, et al. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005;23(34):8606-8612. (Pubitemid 46211502)
19. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer. 2007;120(4):833-843. (Pubitemid 46175404)
20. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA. 2006;295(1):74-80. (Pubitemid 43042692)
21. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer. 2008;44(15):2122-2132.
22. Matsushita Y, Sugihara M, Kaburagi J, et al. Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan. Pharmacoepidemiol Drug Saf. 2010;19(2):196-202.
23. Taylor ML, Wells BJ, Smolak MJ. Statins and cancer: a meta-analysis of case-control studies. Eur J Cancer Prev. 2008;17(3):259-268. (Pubitemid 351549667)
24. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
25. Kwan ML, Habel LA, Flick ED, et al. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat. 2008;109(3):573-579. (Pubitemid 351698864)
26. Harputluoglu H, Dizdar O, Karaahmet F, et al. Post-diagnosis statin use and breast recurrence sites in early stage breast cancer survivors. Breast Cancer Res Treat. 2008;110(3):541. (Pubitemid 351962582)
27. Kumar AS, Benz CC, Shim V, et al. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev. 2008;17(5):1028-1033.
28. Garwood ER, Kumar AS, Baehner FL, et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010;119(1):137-144.
29. Campbell MJ, Esserman LJ, Zhou Y, et al. Breast cancer growth prevention by statins. Cancer Res. 2006;66(17):8707-8714. (Pubitemid 44449187)
30. Katz MS, Minsky BD, Saltz LB, et al. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62(5):1363-1370. (Pubitemid 40982056)
31. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer. 2001;84(7):886-891. (Pubitemid 32385829)
32. Tsai HK, Katz MS, Coen JJ, et al. Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer. Urology. 2006;68(6):1188-1192. (Pubitemid 44880359)
33. Blichert-Toft M, Christiansen P, Mouridsen HT. Danish Breast Cancer Cooperative Group-DBCG: history, organization, and status of scientific achievements at 30-year anniversary. Acta Oncol. 2008;47(4):497-505. (Pubitemid 351878432)
34. Moller S, Jensen MB, Ejlertsen B, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47(4):506-524. (Pubitemid 351878431)
35. Jensen AR, Ewertz M, Cold S, et al. Time trends and regional differences in registration, stage distribution, surgical management and survival of breast cancer in Denmark. Eur J Cancer. 2003;39(12):1783-1793. (Pubitemid 36897617)
36. WHO Collaborating Center for Drug Statistics Methodology. http://www.whocc.no/atcddd/. Accessed January, 2011.
37. Vaughan CJ, Gotto AM Jr. Update on statins: 2003. Circulation. 2004;110(7):886-892. (Pubitemid 39096019)
38. Holmes MD, Chen WY, Li L, et al. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28(9):1467-1472.
39. Kwan ML, Habel LA, Slattery ML, et al. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control. 2007;18(6):613-620. (Pubitemid 46883678)
40. Wernli KJ, Hampton JM, Trentham-Dietz A, et al. Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf. 2011;20(2):131-137.
41. van der Knaap R, Siemes C, Coebergh JW, et al. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer. 2008;112(4):748-757. (Pubitemid 351240568)
42. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med. 2000;342(26):1953-1958. (Pubitemid 30419090)
43. Newcomb PA, Egan KM, Trentham-Dietz A, et al. Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(4):864-871. (Pubitemid 351536417)
44. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
45. Allison PD; SAS Institute. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute; 1995.
46. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005;162(3):199-200. (Pubitemid 41373523)
47. Kubota T, Fujisaki K, Itoh Y, et al. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. Biochem Pharmacol. 2004;67(12):2175-2186. (Pubitemid 38639926)
48. Hansen PS, Andersen E, Andersen KW, et al. Quality control of end results in a Danish adjuvant breast cancer multi-center study. Acta Oncol. 1997;36(7):711-714. (Pubitemid 28078929)
49. Ewertz M, Jensen MB, Gunnarsdottir KA, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 2011;29(1):25-31.
50. Ozdemir BH, Akcali Z, Haberal M. Hypercholesterolemia impairs angiogenesis in patients with breast carcinoma and, therefore, lowers the risk of metastases. Am J Clin Pathol. 2004;122(5):696-703. (Pubitemid 39434750)
51. Bosco JL, Silliman RA, Thwin SS, et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010;63(1):64-74.
52. Friedman GD, Flick ED, Udaltsova N, et al. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008;17(1):27-36. (Pubitemid 351166615)
53. Kumar AS, Campbell M, Benz CC, et al. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes. J Clin Oncol. 2006;24(13):2127. author reply 2127-2128. (Pubitemid 46622124)